Level C· Early human research exploring benefitsProspective StudyPubMed

Autologous minimally manipulated adipose-derived stromal vascular fraction in knee osteoarthritis: Lasting symptom relief and imaging evidence from a 12-month prospective study.

Mangiavini L., Rossi N., Giorgino R., Borelli F., Colombini A., De Luca P.

Prospective Study on Knee Osteoarthritis, Osteoarthritis, published in Knee Surg Sports Traumatol Arthrosc (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Knee Surg Sports Traumatol Arthrosc (2025)
Country
Germany
Reported sample size
—
Source database
PubMed
PMID
41147876
DOI
10.1002/ksa.70149
Citations
1

Abstract (original English)

Purpose To evaluate the safety and efficacy of intra-articular autologous transplantation of adipose-derived connective tissue micrografts rich in stromal vascular fraction (CTM-SVF), obtained using an enzyme-free system (Hy-Tissue® SVF) for knee osteoarthritis (OA). Methods Thirty patients (mean age of 53.3 ± 6.4 years) with Kellgren-Lawrence grade I to III knee OA received a single intra-articular injection of autologous CTM-SVF prepared with the Hy-Tissue SVF concentration system. Follow-ups were set at 3-, 6- and 12-month postinjection. Outcome measures included knee injury and osteoarthritis outcome score (KOOS), pain relief (NRS-11), quality of life (EQ-5D index), magnetic resonance imaging (MRI) scans (whole-organ magnetic resonance imaging score-WORMS, T2 mapping), OA serum biomarkers, safety and local tolerability. Results One patient discontinued prematurely. KOOS improved significantly, with the highest mean score (68.7 ± 14.9) at 3 months and the majority of patients achieving a ≥ 9-point increase from baseline. Results were maintained through 12 months. NRS-11 and EQ-5D also improved through 12 months, with more than 80% of patients meeting the NRS-11 MCID at every timepoint. EQ-VAS, however, showed only a modest responder rate (10%). MRI revealed improvements in T2 relaxation times, while OA serum biomarkers (evaluated at 3 months postinjection) indicated a signif

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research